Intercepting Cancer's Survival Mechanism


Aravive Biologics and Versartis are now Aravive, Inc.

14 October 2018 | Aravive Biologics and Versartis Complete Merger

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival.

Aravive’s products in development are based on technology originated at Stanford University. The company is based in Houston, Texas and funded in part by a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT).